Pure Global
NCT05714423

Outcomes in Lower Pole Kidney Stone Management Using Mini-PCNL Compared With Retrograde Intra Renal Surgery

Outcomes in Lower Pole Kidney Stone Management Using Mini-PCNL Compared With Retrograde Intra Renal Surgery: A Randomized Controlled Trial
Services Hospital, Lahore·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Kidney Stone
Drug/Device/Intervention
Mini-PCNL
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Services Hospital, Lahore
Location
Lahore, Pakistan
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2020
End date
Dec 31, 2022
Enrollment
150 participants
Primary outcome

Stone Clearance

Summary

Due to the anatomic characteristics of the lower calyx, lower pole stones are difficult to be
 eliminated through the ureter, even if the stones had been fragmented. Retrograde intrarenal
 surgery (RIRS) can be used to deal with lower pole stones of 1.0-2.0 cm, while percutaneous
 nephrolithotripsy (PCNL) is mainly used to deal with lower pole stones with larger diameter
 or when RIRS failed to resolve the stone. This study was conducted to compare mini PCNL and
 retrograde intrarenal surgery (RIRS) for the management of lower pole kidney stones in terms
 of efficacy.

ICD-10 classifications
Kidney dialysisSmall kidney, unspecifiedDisorder of kidney and ureter, unspecifiedInjury of kidneyUnspecified kidney failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05714423
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05714423 through Pure Global AI's free database. This phase not specified trial is sponsored by Services Hospital, Lahore and is currently Completed. The study focuses on Kidney Stone. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.